United Therapeutics Price Target Increased to $105.00 by Analysts at Guggenheim (UTHR)
Investment analysts at Guggenheim boosted their price target on shares of United Therapeutics (NASDAQ:UTHR) from $101.00 to $105.00 in a note issued to investors on Tuesday. Guggenheim’s price objective suggests a potential downside of 10.89% from the stock’s previous close.
United Therapeutics (NASDAQ:UTHR) traded down 1.91% on Tuesday, hitting $115.58. The stock had a trading volume of 422,644 shares. United Therapeutics has a one year low of $70.95 and a one year high of $118.76. The stock’s 50-day moving average is $92.3 and its 200-day moving average is $95.55. The company has a market cap of $5.463 billion and a P/E ratio of 22.77.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter in the prior year, the company posted $1.52 earnings per share. The company’s quarterly revenue was up 15.0% on a year-over-year basis. Analysts expect that United Therapeutics will post $8.56 EPS for the current fiscal year.
In other United Therapeutics news, EVP Paul A. Mahon sold 5,000 shares of United Therapeutics stock on the open market in a transaction dated Thursday, August 28th. The shares were sold at an average price of $92.07, for a total value of $460,350.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Other equities research analysts have also recently issued reports about the stock. Analysts at Wedbush raised their price target on shares of United Therapeutics from $133.00 to $141.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Standpoint Research raised their price target on shares of United Therapeutics from $118.00 to $140.00 in a research note on Friday. They now have a “buy” rating on the stock. Finally, analysts at Zacks upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Thursday, August 21st. They now have a $112.00 price target on the stock. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. United Therapeutics currently has an average rating of “Buy” and an average price target of $106.80.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.